reports
QIAGEN collaborates with McGill University to advance microbiome resea...
QIAGEN collaborates with McGill University to advance microbiome research QIAGEN and McGill University to collaborate on microbiome research projects to generate evidence-based knowledge for medicine and public health // McGill will serve as a beta-testing site for new QIAGEN microbiome solutions // Partnership strengthens QIAGEN’s efforts in microbiome research while supporting innovation at the McGill Centre for Microbiome Research Montreal, Canada, and Venlo, the Netherlands, Nov. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collab...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Benoit Valleaux
- Emira Sagaama
- Steven Gould
SOON SONOVA HOLDING AG
LRC LEGRAND
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
MT ARCELORMITTAL SA
CA CARREFOUR SA
CBK COMMERZBANK AG
SW SODEXO SA
RHM RHEINMETALL AG
KBC KBC GROUP N.V.
TEP TELEPERFORMANCE SE
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
ENEL ENEL SPA
ASM ASM INTERNATIONAL N.V.
NEM NEMETSCHEK SE
RAA RATIONAL AG
EDW EDP RENOVAVEIS SA
AMS AMADEUS IT GROUP SA CLASS A
AUTO AUTO TRADER GROUP PLC
DHER DELIVERY HERO SE
ADYEN ADYEN NV
DTG DAIMLER TRUCK
ARM ARM HOLDINGS PLC
TEN TENARIS S.A.
QGEN QIAGEN N.V.
ALIV SDB AUTOLIV INC.
- Benoit Valleaux
- Emira Sagaama
- Steven Gould
SOON SONOVA HOLDING AG
LRC LEGRAND
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
MT ARCELORMITTAL SA
CA CARREFOUR SA
CBK COMMERZBANK AG
SW SODEXO SA
RHM RHEINMETALL AG
KBC KBC GROUP N.V.
TEP TELEPERFORMANCE SE
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
ENEL ENEL SPA
ASM ASM INTERNATIONAL N.V.
NEM NEMETSCHEK SE
RAA RATIONAL AG
EDW EDP RENOVAVEIS SA
AMS AMADEUS IT GROUP SA CLASS A
AUTO AUTO TRADER GROUP PLC
DHER DELIVERY HERO SE
ADYEN ADYEN NV
DTG DAIMLER TRUCK
ARM ARM HOLDINGS PLC
TEN TENARIS S.A.
QGEN QIAGEN N.V.
ALIV SDB AUTOLIV INC.
- Oliver Metzger
- Stephan Wulf
Qiagen : Strong Q3 2023 results drive rise in EPS guidance
>Q3 results above our and the consensus estimates - Qiagen reported a strong set of Q3 results. Sales at CER came in at $ 502m, 1% above our ($ 495m), 2% above consensus estimates ($ 492m) and ahead of the company’s guidance of $ 495m. Y-o-y, sales increased by 5.5% despite Qiagen’s solution to gradually exit the NeuMoDx business. The company benefited predominantly from tailwind, driven by continuously strong growth of QuantiFERON (+10% to $ 122m) and QIAstat-DX (+40...
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-...
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 // Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.58 CER ahead of outlook for at least $0.55 CER // +10% CER growth in Diagnostic solutions leads results among product groups // 29.6% adj. operating income margin up 3 percentage points vs. 26.6% in Q3 2023 // Free cash flow up 73% to $364 ...
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis pa...
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion // QIAstat-Dx delivers results in about one hour with real-...
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve pre...
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions // With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship // FDA decision marks third positive U.S. regulatory outcome for QIAstat-Dx to date in 2024 Germantown, Maryland, and Venlo, the...
QIAGEN expands automated liquid biopsy portfolio to enhance oncology, ...
QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications Portfolio expansion reinforces QIAGEN’s leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows // New ccfDNA Kit upgrade with urine protocol for use on EZ1 and 2 instruments designed to enhance liquid biopsy workflows for cancer research // New QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for use in downstream applications Venlo, the Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN (...
QIAGEN N.V. to release results for Q3 2024 and hold webcast
QIAGEN N.V. to release results for Q3 2024 and hold webcast Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024. Press release date / time: Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Serv...
Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerg...
Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer QIAGEN’s leading tuberculosis blood test QuantiFERON®-TB Gold Plus remains crucial for detection of latent tuberculosis infection, aiding in breaking the cycle of disease transmission // Over 35 top tuberculosis experts to discuss critical topics such as advancements in diagnostics and new treatment strategies // CPD- and CME-accredited event highlights the need for renewed global efforts for tuberculosis control Venlo, the Netherlands, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Thousands of h...
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in ...
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology Expands range of applications for successful QIAcuity digital PCR platforms, now entering the clinical space across North America and the EU // Provides absolute quantitation, essential for precise monitoring of low-abundance targets in clinical diagnostics // Enhances lab efficiency and reduces costs with all-in-one instrument for either IVD assays or tests designed and used by laboratories, user-friendly software and flexible scheduling features Venlo, the Netherlands, Sept. 30, 2024 (GLOBE NEWSWIRE) -- QIA...
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic t...
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification confirms that QIAGEN’s devices meet the stringent safety, quality and performance standards for in-vitro diagnostics in Europe // QIAGEN on track to transition over 180 products to new IVDR regulatory framework Venlo, the Netherlands, Sept. 26, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfu...
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution fo...
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA // Cell-free DNA in urine can provide important information to data not found in blood samples Venlo, The Netherlands, and Hombrechtikon, Sw...
QIAGEN and Bode Technology partner to advance use of GEDmatch PRO fore...
QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains // Collaboration ensures GEDmatch PRO development remains focused on the needs of forensic genealogists and investigators in the U.S. and other countries worldwide // Partnership builds on QIAGEN’s leading global position in providing extensive portfolio for use in human identification and forensics Venlo, the...
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays ...
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications // QIAcuity digital PCR enables accurate and sensitive detection of low-abundance pathogens, copy number alterations and identification of rare mutations // Portfolio expansion and partnerships support increased adoption of QIAcuity across multiple application areas Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGE...
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and d...
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs Advanced PCR-based screening platform deployed nationwide across 30 laboratories provides new capabilities to detect malaria, HIV, HCV, and HBV in blood donations // Advanced capabilities support epidemiological surveillance of ongoing dengue outbreak in Brazil with unique chemistry developed by QIAGEN and Bio-Manguinhos/Fiocruz // Partnership highlights QIAGEN’s commitment to custom and OEM solutions, technology transfer and long-term support Venlo, the Netherland...
QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IV...
QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s disease QIAGEN to develop the first QIAstat-Dx IVD panel for neurodegenerative applications // New QIAstat-Dx panel to identify APOE genotypes, one of many factors considered in the diagnosis of patients with Alzheimer’s Disease // Collaboration set to launch the first commercially available IVD Kit for APOE genotyping Venlo, the Netherlands, Sept. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has e...
QIAGEN expands QIAstat-Dx into precision medicine through partnership ...
QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases New agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases // QIAGEN’s syndromic testing platform QIAstat-Dx enables specialty care providers to make fast decisions about patients’ eligibility for investigational precision medicines Venlo, the Netherlands, Aug. 28, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its Master Collaboration Agreement with AstraZeneca to d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.